New research debuted at the American Diabetes Association’s 72nd Annual Scientific Session suggests eating raisins three times a day may significantly lower postprandial (post-meal) glucose levels when compared to common alternative snacks of equal caloric value. The study was conducted at the Louisville Metabolic and Atherosclerosis Center (L-MARC) by lead researcher, Harold Bays, MD, medical director and president of L-MARC.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56845-california-raisin-marketing-board-raisins-reduce-post-meal-blood-sugar
Through thousands of hours meeting with women from Dallas to Taipei, Sao Paulo to Paris, Neutrogena® uncovered a universal truth – women are stepping back to examine what’s possible in their lives so they can pursue their dreams. Always on a mission to create, innovate, and rethink what’s possible in skincare, Neutrogena® identified this shared value and was inspired to launch its first-ever global campaign: “Neutrogena. See What’s Possible.™”
“Neutrogena® started as a dream, and through scientific discovery, creative thinking and the resilience to defy expectations without any compromises, a brand was born,” said Alicia Sontag, President, Beauty Care, Johnson & Johnson Consumer Inc. “We support women around the world and are proud to help them put their best face forward as they pursue their own dreams – big or small.”
The “Neutrogena. See What’s Possible™” campaign will debut with a commercial voiced by Brand Ambassador and creative consultant Kerry Washington which features real women following their passions. The empowering video brings to life the brand’s point of view on beauty – what really makes a woman beautiful is the ability to look in the mirror and know that anything is possible. In addition, educational and inspiring digital content designed to encourage her along her journey will be leveraged through social platforms in over 27 countries around the world, making this the largest digitally-driven campaign the brand has ever executed.
To view the multimedia release go to:
http://www.multivu.com/players/English/7770451-neutrogena-see-what-s-possible/
SimplexCalc is a multivariable desktop calculator for Windows. It is small and simple to use but with much power and versatility underneath. It can be used as an enhanced elementary, scientific, financial or expression calculator.
In addition to arithmetic operation, more than hundred built-in constants and functions can also be used in your expression.
SimplexCalc also has the unlimited ability to extend itself by using custom (user-defined) variables. You can add your own variables for SimplexCalc in order to tackle complex problems with ease and fun. Even you can compile formula once and then calculate the result many times with different variable values.
With the brilliant designs and powerful features of SimplexCalc, you can bring spectacular results to your calculating routines.
MultiplexCalc is a multipurpose and comprehensive desktop calculator for Windows. It is small and simple to use but with much power and versatility underneath. It can be used as an enhanced elementary, scientific, financial or expression calculator. MultiplexCalc contains more than hundred internal constants and functions (algebraic, trigonometric, hyperbolic, transcendental, etc;) to satisfy your needs to solve problems ranging from simple elementary algebra to complex equations. Its underling implementation encompasses high precision, sturdiness and multi-functionality.
MultiplexCalc also has the unlimited ability to extend itself by using user-defined variables. You can add your own variables to MultiplexCalc in order to convenience your work. Any instance of a formula can be parsed once, and calculated many times with different variable values.
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. Accelrys Insight and Accelrys Insight for Excel offer research scientists an entirely new way of accessing, visualizing and analyzing data that is locked in disparate locations across internal discovery teams and networked external partners, helping to lower long-standing barriers to bringing innovative therapeutics to market faster and more cost effectively.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62191-accelrys-insight-next-generation-decision-making-in-scientific-discovery
Living Proof launches its latest scientific breakthrough in hair care: Restore.
Remember your hair when you were a kid? It was shiny, smooth, soft and strong – the envy of your Mom. It wasn’t fussed over. It barely needed to be brushed. But years of blow drying, flat ironing, teasing, bleaching and coloring have left your hair dry and damaged.
Youthful hair is naturally healthy, beautiful hair. We all had it once. What if you could bring it back?
To view Multimedia News Release, go to http://www.multivu.com/mnr/52656-living-proof-restore-salvation-for-dry-or-damaged-hair
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
